Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ipsen
Biotech
Ipsen posts mixed liver disease data on Intercept, CymaBay rival
The phase 3 trial publication provides a closer look at how the liver therapy holds up against Intercept’s Ocaliva and CymaBay’s own challenger.
Nick Paul Taylor
Nov 14, 2023 5:55am
Ipsen still out of luck as EC rejects rare disease drug
Jul 20, 2023 6:32am
Ipsen, Genfit report phase 3 rare liver disease success
Jun 30, 2023 6:15am
Ipsen wins FDA AdComm rare disease vote in split decision
Jun 29, 2023 6:00am
Ariceum bolsters radiopharma efforts with Theragnostics buy
Jun 1, 2023 10:35am
Ipsen's rare disease candidate rejected after mounting delays
Dec 27, 2022 10:44am